






























抗核抗體型態臨床相關性對照表

下表中“AC”為 Anti-Cell 縮寫，用滑鼠雙擊 AC 代碼可連結到國際核型共識網站 ANA 型態頁面能獲取更詳細的資訊

代碼	AC Pattern	範例圖片	對應抗原	Follow-up tests	臨床意義
AC-0	Negative		不適用	不適用	不適用
AC-1	Homogeneous		dsDNA, nucleosomes, histones	Anti-dsDNA anti- Nucleosome anti-Histone	全身性紅斑狼瘡 (SLE)*、藥物性狼瘡 (drug-induced lupus)、少年型特發性關節炎 (juvenile idiopathic arthritis)、慢性自體免疫性肝炎 (Autoimmune Hepatitis)
AC-2	Dense Fine Speckled		DFS70/LEDGF	Anti-DFS-70	常在沒有自體免疫疾病的病人中單獨出現，少見於修格連氏症、全身性硬化症和全身性紅斑狼瘡，但當此型態和其混合出現仍可能和自體免疫疾病有關，需使用專門檢測 DFS70 的試藥確認
AC-3	Centromere		CENP-A/B (C)	Anti-CENP-A Anti-CENP-B	侷限硬皮型全身性硬化症 (Limited cutaneous SSc)、原發性膽道硬化症 (PBC)
AC-4	Fine Speckled		SS-A/Ro, SS-B/La, Mi-2, TIF1γ, TIF1β, Ku	Myositis Profile Anti-SSA Anti-SSB	修格連氏症 (SjS)、全身性紅斑狼瘡 (SLE)、皮肌炎 (dermatomyositis)、系統性硬皮症/多發性肌炎重疊性綜合症 (SSc/PM overlap syndrome)
AC-5	Coarse speckled		hnRNP, U1RNP, Sm, RNA polymerase III	SSc profile Anti-Sm Anti-nRNP Anti-Scl-70	混合型結締組織疾病 (MCTD)、全身性紅斑狼瘡 (SLE)、全身性硬化症 (SSc)
AC-6	Multiple Nuclear dots		Sp-100, PML proteins, MJ/NXP- 2	ALD profile Myositis Profile	原發性膽道硬化症 (PBC)、全身性自體免疫風濕病 (SARD)、皮肌炎 (dermatomyositis)

<u>AC-7</u>	Few Nuclear dots		p80-coilin, SMN	修格連氏症 (SjS)、全身性紅斑狼瘡 (SLE)、全身性硬化症 (SSc)、多發性肌炎 (PM)、無症狀個人
<u>AC-8</u>	Homogeneous Nucleolar		PM/Scl-75, PM/Scl-100, Th/To, B23/nucleophosmin, nucleolin, No55/SC65	Myositis panel SSc profile Anti-Scl-70 全身性硬化症 (SSc)、全身性硬化症 /多發性肌炎重疊症狀(SSc/PM overlap syndrome)
<u>AC-9</u>	Clampy Nucleolar		U3-snoRNP/fibrillarin	SSc profile 全身性硬化症 (SSc)
<u>AC-10</u>	Punctate Nucleolar		RNA polymerase I, hUBF/NOR-90	SSc profile Anti-Sm Anti-RNP 全身性硬化症 (SSc)、修格連氏症 (SjS)
<u>AC-11</u>	Smooth Nuclear Envelope		lamins A, B,C, or lamin-associated proteins	全身性紅斑狼瘡 (SLE)、修格連氏症 (SjS)、血清陰性關節炎 (seronegative arthritis)
<u>AC-12</u>	Punctate Nuclear Envelope		nuclear pore complex proteins	Anti-gp210 ALD Profile 原發性膽道硬化症 (PBC)
<u>AC-13</u>	PCNA-like		PCNA	全身性紅斑狼瘡 (SLE) *以往認為此型態對 SLE 的專一性非常高，但後來此說法又出現爭議
<u>AC-14</u>	CENP-F-like		CENP-F	與癌症 (乳癌、肺癌、大腸癌、淋巴癌、卵巢癌、腦癌)和其他疾病 (Crohn's disease、autoimmune liver disease, SjS, graft-versus-host disease)有關

AC-15	Cytoplasmic Fibrillar		alpha-actinin, vinculin	ASMA	混合型結締組織疾病 (MCTD)、慢性活動性肝炎 (chronic active hepatitis)、肝硬化 (liver cirrhosis)、重症肌無力、克隆氏症 (Crohn's disease)、原發性膽道硬化症 (PBC)、長期血液透析，少見於全身性自體免疫風濕病 (SARD)
AC-16	Cytoplasmic Fibrillar Filamentous		vimentin, cytokeratins, tropomyosin	ASMA	感染或發炎性病症、長期血液透析、酒精性肝病、全身性自體免疫風濕病 (SARD)、乾癬 (psoriasis)，健康族群
AC-17	Cytoplasmic Fibrillar Segmental		alpha-actinin, vinculin	ASMA	重症肌無力 (myasthenia gravis)、克隆氏症 (Crohn's disease)、潰瘍性結腸炎 (ulcerative colitis)
AC-18	Cytoplasmic discrete dots		GW182, Su/Ago2		原發性膽道硬化症 (PBC)、全身性自體免疫風濕病 (SARD)、神經性 (neurological) 和自體免疫病症
AC-19	Cytoplasmic dense fine speckled		PL-7, PL-12, ribosomal P proteins, SRP	Myositis Profile Anti-ribosomal P	抗合成酶症候群 (anti-synthetase syndrome)、多發性肌炎/皮肌炎 (PM/DM)、免疫介導壞死性肌炎 (IMNM)、紅斑性狼瘡 (SLE)、幼年型紅斑性狼瘡症 (juvenile SLE)、神經精神病系統性紅斑性狼瘡 (neuropsychiatric SLE)
AC-20	Cytoplasmic fine speckled		Jo-1/histidyl-tRNA synthetase	Myositis Profile Anti-Jo-1	抗合成酶症候群 (anti-synthetase syndrome)、多發性肌炎/皮肌炎 (PM/DM)、侷限全身性硬化症 (limited SSc)、原發性肋膜積液 (idiopathic pleural effusion)
AC-21	Cytoplasmic reticular/AMA		PDC-E2/M2, BCOADC-E2, OGDC-E2, E1 α subunit of PDC, E3BP/protein X	AMA ALD profile	常見於原發性膽道硬化症 (PBC)、全身性硬化症 (SSc)、少見於全身性自體免疫風濕病 (SARD)
AC-22	Polar/Golgi-like		giantin/macrogolg in, golgin- 95/GM130, golgin-160, golgin-97, golgin- 245		少見於修格連氏症 (SjS)、全身性紅斑狼瘡 (SLE)、類風濕性關節炎、混合型結締組織疾病、肉芽腫性血管炎、原發性小腦性運動失調症、副腫瘤性小腦變性、病毒感染。
AC-23	Rods and rings		IMPDH2		經過干擾素或 ribavirin 治療之 C 型肝炎病患

<u>AC-24</u>	Centrosome		pericentrin, ninein, Cep250, Cep110	少見於全身性硬化症 (SSc)、雷諾氏現象、病毒和黴 菌感染。對疾病的陽性預測價值 (positive predict value) 不大。可能單獨或與其他型態合併出現在在雷 諾氏症 (Raynaud's phenomenon)、局部性硬皮症 (localized scleroderma)、系統性硬皮症 (SSc)、紅斑性 狼瘡 (SLE)與風濕性關節炎 (RA)的病人身上。
<u>AC-25</u>	Spindle fibers		HsEg5	少見於修格連氏症 (SjS)、全身性紅斑狼瘡、其他結 締組織疾病。對疾病的陽性預測價值 (positive predict value) 不大。
<u>AC-26</u>	NuMA-like		NuMA	修格連氏症 (SjS)、全身性紅斑狼瘡 (SLE)
<u>AC-27</u>	Intercellular bridge		無	少見於全身性硬化症 (SSc)、雷諾氏現象、惡性腫瘤
<u>AC-28</u>	Mitotic chromosomal envelope		modified histone H3, MCA-1	少見於圓盤狀紅斑狼瘡、慢性淋巴性白血病、修格 連氏症 (SjS)、風濕性多肌痛症
<u>AC-29</u>	DNA topoisomerase I (Topo-1 like)		DNA topoisomerase I	SSc Profile Anti-Scl-70 系統性硬皮症 (SSc) - 以瀰漫型系統性硬皮症 (diffuse cutaneous SSc) 為主

附註：判讀 ANA 數據時，除了考慮結果是否高於參考值以外，應考慮效價，有 20-30% 健康人 ANA titer $\geq 1:40$; 10-12% 健康人 ANA titer $> 1:80$; 5% ANA titer $> 1:160$; 3% ANA titer $> 1:320$

參考資料：

1. 抗核抗體國際合型共識網站 (<https://www.anapatterns.org/>)
2. Arch Pathol Lab Med. 2000 Jan;124(1):71-81.